Arbutus Biopharma Corp revenue
Arbutus Biopharma Corp's revenue was $14.1m in fiscal 2025, up 128.2% on the year before. Since fiscal 2011 ($16.8m) it has grown at a compound -1.3% a year. Over the last twelve months it was $182m.
Revenue history
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 14 | 15 | 15 | 23 | 1 | 11 | 6 | 6 | 7 | 11 | 39 | 18 | 6 | 14 | 182 |
| Growth on the year before | — | −16.1% | +9.6% | −3.3% | +55.7% | −93.6% | +617.6% | −44.4% | +1.1% | +15.0% | +58.9% | +255.1% | −53.5% | −66.0% | +128.2% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Collaboration and Contracts | $12.6M | 89.5% | ▲ 221.5% |
| Non Cash Royalty | $1.5M | 10.5% | ▼ 34.2% |
From Arbutus Biopharma Corp's 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Arbutus Biopharma Corp | $182m | 1078.8% | 97.6% |
| Urogen Pharma Ltd. | $189m | 100.3% | 37.6% |
| Nuvation Bio Inc. | $170m | 1083.6% | — |
| Valneva SE | $197m | 7.6% | — |
| Immunitybio, Inc. | $166m | 192.9% | 554.3% |
| Beam Therapeutics Inc. | $156m | 158.9% | 24.9% |
Compare with peers
- Urogen Pharma Ltd. revenue
- Nuvation Bio Inc. revenue
- Valneva SE revenue
- Immunitybio, Inc. revenue
- Beam Therapeutics Inc. revenue
Head to head: ABUS vs URGNABUS vs NUVBABUS vs VALNABUS vs IBRX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies